Avalon Globocare 株価情報 (NASDAQ: ALBT)

最新ニュース Avalon Globocare (NASDAQ:ALBT) 株価情報

Avalon Globocare

Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment, which is the key revenue driver, and the laboratory testing services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.

Avalon Globocare Corp

AllianceBlock - United States Dollar

<ul>
<li>KEYNOTE-689 marks the first positive trial in more than two decades for patients with resected locally advanced head and neck squamous cell carcinoma (LA-HNSCC)</li>
<li>Results to be presented at American Association for Cancer Research (AACR) Annual Meeting 2025 during a Plenary Session and included in official meeting press program</li>
</ul>

News

Reported Sunday, Merck's Phase 3 KEYNOTE-689 Data Shows KEYTRUDA Significantly Improves Event-Free Survival As Perioperative Therapy In Locally Advanced Head And Neck Cancer

The Nasdaq has staged a remarkable turnaround in April, transforming from what was initially dubbed the &#8220;worst April for the stock market since the Great Depression&#8221; to posting gains for the month, a recovery that&#8217;s drawing attention from prominent market analysts.
What Happened: On Sunday, Tom Lee, Head of Research at Fundstrat Global Advisors, endorsed Treasury Secretary Scott Bessent&#8216;s observation about the market&#8217;s resilience, describing the equity recovery as a &#8220;White House put&#8221; – suggesting government policies are providing a floor for market values.
&#8220;Equity recovery cannot be ignored,&#8221; Lee wrote on X, responding to Bessent&#8217;s post highlighting the dramatic shift in market narrative.
The S&amp;P 500 index, tracked by SPDR S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), has gained 10.89% since its April 8 low of 4,982, currently trading around 5,525. This recovery follows concerns over potential tariff impacts and recession risks that had previously shaken investors. Meanwhile, the Nasdaq 100, tracked by Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), has surged 13.70% from its low of 17,090 on the same day, now trading at 19,432.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f440;&#x1f440;&#x1f440; &#x1f447; Agree &#x1f4af;&#x1f4af;&#x1f4af;&#x1f4af; Equity recovery cannot be ignored PS: This is also known as a "White House" put<a href="https://twitter.com/hashtag/sundayvibes?src=hash&amp;ref_src=twsrc%5Etfw">#sundayvibes</a> <a href="https://t.co/5rXpcLFYHb">https://t.co/5rXpcLFYHb</a>
&mdash; Thomas (Tom) Lee (not drummer) FSInsight.com (@fundstrat) <a href="https://twitter.com/fundstrat/status/1916562502281810374?ref_src=twsrc%5Etfw">April 27, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The rebound contrasts sharply with warnings from analysts like Chris Senyek of Wolfe Research, who recently cautioned that the S&amp;P 500 could plunge as low as 3,700 points – a potential 37% decline from January levels – if tariff-related uncertainty <a href="https://www.benzinga.com/markets/equities/25/04/45004528/sp-500-could-crash-37-to-3700-if-tariff-fallout-triggers-recession-warns-wolfe-research">triggers a recession in 2025</a>.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45031324/bitcoin-ethereum-dogecoin-drop-as-stock-futures-slide-willy-woo-says-all-dips-are-for-buying-with-btc-eyeing-all-time-highs">Bitcoin, Ethereum, Dogecoin Drop As Stock Futures Slide: Willy Woo Says &#8216;All Dips Are For Buying&#8217; With BTC Eyeing &#8216;All-Time Highs</a>
Why It Matters: Market volatility has been exacerbated by President Donald Trump&#8216;s tariff announcements in early April, particularly regarding China. Despite the president&#8217;s recent statements that he would maintain tariffs without &#8220;substantial&#8221; concessions from Beijing, markets have shown surprising resilience.
Technical analysts remain cautious about the sustainability of the recovery. JPMorgan&#8216;s Jason Hunter has identified the 5,425-5,650 range as key resistance for the S&amp;P 500, <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/45011336/sp-500-magnificent-7-hit-resistance-analyst-warns-of-more-pain-before-gain">suggesting the index could retreat to 4,500-4,800</a> before establishing a &#8220;more durable bottom.&#8221;
The &#8220;Magnificent 7&#8221; tech stocks that have driven much of the market&#8217;s performance in recent years are &#8220;consolidating within volatile ranges below their respective breakdown levels,&#8221; according to Hunter, indicating <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/45011336/sp-500-magnificent-7-hit-resistance-analyst-warns-of-more-pain-before-gain">potential challenges ahead for market leaders</a> including Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
Photo: JHVEPhoto / Shuttesstock
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45030669/chamath-palihapitiya-says-nvidia-is-huaweis-new-target-a-national-champion-that-crushed-tech-giants-with-a-low-end-disruptor-strategy">Chamath Palihapitiya Says Nvidia Is Huawei&#8217;s &#8216;New Target&#8217; — A &#8216;National Champion&#8217; That Crushed Tech Giants With A &#8216;Low-End Disruptor&#8217; Strategy</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Economics

Markets

AAPL

MSFT

NVDA

Tom Lee Backs Scott Bessent 'White House Put' Theory As Nasdaq Flips From Worst April Start Since Great Depression To Major Comeback

Tesla Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Chinese division is developing an affordable version of the popular Model Y crossover SUV.
What Happened: The model, dubbed the ‘E80,' will reportedly be a toned-down version of the new Model Y and feature a 50-55 kWh battery, smaller wheels, fabric seats with no ventilation, and no rear display, among other omissions, <a href="https://www.teslarati.com/tesla-china-affordable-model-y-e80-price-features-more/">notes</a> Teslarati in a report published on Sunday.
The model could be released in the latter half of 2025 or sometime in 2026, but it could also depend on how the new Model Y performs in China, the report suggests.
As for the pricing, the new variant could be offered for around CNY 150,000-210,000 or $20,500-$28,800.
Tesla did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
Why It Matters: The news comes in as Elon Musk's EV giant had shared plans to release <a href="https://www.benzinga.com/25/04/44942792/tesla-q1-earnings-call-company-says-more-affordable-models-launching-this-year">more affordable models</a> this year at the company's Q1 2025 earnings call with investors.
Tesla has already released affordable trim levels for its models before. Recently, the company released a cheaper <a href="https://www.benzinga.com/markets/equities/25/04/44755221/tesla-unveils-new-cybertruck-long-range-trim-with-a-362-mile-range-and-reduced-features">RWD LR (Long Range) version</a> with fewer features and even altered the marketing strategy for the vehicle to focus on its utilitarian properties.
The company also recently <a href="https://www.benzinga.com/tech/25/04/45004433/tesla-rolls-out-free-fsd-transfers-on-all-us-models-including-cybertruck-amid-poor-sales">announced new promotions </a>for its entire line-up in the U.S., including free FSD transfers, amid declining sales figures, as well as <a href="https://www.benzinga.com/25/04/45002083/court-documents-reveal-charges-filed-against-dc-tesla-vandalism-suspect-report">increased hostility </a>towards Musk's businesses.
Price Action: TSLA currently trades for $284.95 on the NASDAQ, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/45029648/tesla-stock-skyrockets-20-following-elon-musks-return-and-shift-from-doge">Tesla Stock Skyrockets 20% Following Elon Musk&#8217;s Return and Shift From DOGE&nbsp;</a></li>
</ul>
Image Via Shutterstock

Asia

Tech

General

TSLA

Tesla Reportedly Developing A Cheaper Model Y 'E80' Variant With Fewer Features In China

SWTX

Reported Sunday, SpringWorks Anticipates EMA CHMP Ruling On Nirogacestat For Desmoid Tumor Therapy In Q2 2025

Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) –
– Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for Merck KGaA, Darmstadt, Germany's Healthcare business –
– SpringWorks Therapeutics is a U.S. biopharmaceutical company with a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas –
– Planned acquisition will strengthen the presence of Merck KGaA, Darmstadt, Germany's Healthcare business in the United States and expand reach of SpringWorks' therapeutic innovations to more patients with rare tumors worldwide –

MKKGY

SpringWorks Therapeutics To Be Acquired by Merck KGaA, In $3.9B Deal To Expand Rare Tumor Portfolio

<ul>
<li>VYVGART&#xAE; is first-and-only targeted IgG Fc-antibody fragment for CIDP</li>
<li>First novel mechanism of action for CIDP treatment in more than 30 years</li>
<li>CHMP positive opinion based on ADHERE data, the largest ever CIDP clinical trial</li>
<li>European Commission (EC) decision on marketing authorization application (MAA)&nbsp;expected within approximately two months</li>
</ul>

ARGX

argenx's VYVGART For CIDP Gains Positive CHMP Opinion Based On Data From ADHERE Clinical Trial

RVMD

Reported Sunday, Revolution Medicines Initial Phase 1 Study Data Show Zoldonrasib Achieves 61% Objective Response Rate in KRAS G12D Mutant NSCLC

Ace investor and fund manager, Cathie Wood, is doubling down on Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), reaffirming her confidence in the company's ability to lead the enterprise AI race, as shifting market dynamics disrupt established players in this space.
What Happened: On Saturday, the Ark Invest CEO quoted a post on X by Brett Winton, the firm's chief futurist, who simply wrote, "Excel. Will. Die." The post predicts the eventual downfall of Microsoft Corp.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) widely used spreadsheet software, which has been a mainstay in office environments for decades.
See More: <a href="https://www.benzinga.com/news/25/04/45019174/palantir-stock-soars-on-defense-deals-whats-going-on">Palantir Stock Soars On Defense Deals: What&#8217;s Going On?</a>
In response to the post, Wood questioned how Microsoft and its enterprise clients would navigate the &#8220;massive disruption,&#8221; before saying, &#8220;Palantir comes to mind.&#8221; 
According to Wood, Palantir CEO Alex Karp believes that the company will become the largest pure-play enterprise AI software company in the world, &#8220;I believe him,&#8221; she says.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I wonder how <a href="https://twitter.com/search?q=%24MSFT&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$MSFT</a> and its enterprise clients are going to manage through this massive disruption. Palantir comes to mind. CEO Alex Karp believes that <a href="https://twitter.com/search?q=%24PLTR&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$PLTR</a> will become the largest pure play enterprise AI software company in the world. I believe him. <a href="https://t.co/pFJxPueKdn">https://t.co/pFJxPueKdn</a>
&mdash; Cathie Wood (@CathieDWood) <a href="https://twitter.com/CathieDWood/status/1916166595593805966?ref_src=twsrc%5Etfw">April 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Palantir is now Ark Invest's <a href="https://cathiesark.com/ark-funds-combined/complete-holdings">second-largest holding</a> after Tesla, with a stake valued at $640 million, representing about 7% of its total assets under management across its family of funds.
Microsoft has made significant headway in enterprise AI, with the segment already sporting a <a href="https://benzinga.com/markets/equities/25/01/43327008/microsofts-13-billion-run-rate-and-openai-azure-deal-spark-surge-in-enterprise-demand-for-ai-solutions-just-first-tranche-of-future-growth-potential">$13 billion annual run rate</a>, a figure that is nearly 5 times Palantir&#8217;s annual revenue in 2024. However, the latter is gaining ground rather quickly and is already pulling ahead in sectors such as defense. 
While Microsoft continues to pursue cloud dominance, <a href="https://benzinga.com/trading-ideas/technicals/25/04/44947382/palantir-rolls-out-tanks-microsoft-builds-clouds-whos-winning-ais-next-frontier">Palantir is inking partnerships</a> with major defense contractors and is in the process of building a futuristic AI-powered tank. 
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td class="has-text-align-center" data-align="center">Stock / ETF</td>
<td class="has-text-align-center" data-align="center">YTD Performance</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</td>
<td class="has-text-align-center" data-align="center">-6.39%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>)</td>
<td class="has-text-align-center" data-align="center">+49.99%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Ark Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#BATS">ARKK</a>)</td>
<td class="has-text-align-center" data-align="center">-10.35%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Ark Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>)</td>
<td class="has-text-align-center" data-align="center">-4.89%</td>
</tr>
</tbody>
</table>
</figure>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="141" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28012832/Screenshot-2025-04-28-at-10.58.18-AM-1024x141.png" alt="" class="wp-image-890106" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28012832/Screenshot-2025-04-28-at-10.58.18-AM-1024x141.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28012832/Screenshot-2025-04-28-at-10.58.18-AM-300x41.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28012832/Screenshot-2025-04-28-at-10.58.18-AM-768x106.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28012832/Screenshot-2025-04-28-at-10.58.18-AM-1536x211.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28012832/Screenshot-2025-04-28-at-10.58.18-AM.png 1616w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Palantir scores remarkably well on Benzinga&#8217;s Stock Edge Rankings, with a strong price trend in the short, medium, and long terms, but how does it compare with Microsoft? Sign up for <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Benzinga Edge</a> to find out.
Photo courtesy: slyellow / Shutterstock.com
Read More: <a href="https://www.benzinga.com/25/04/45031447/elon-musk-says-the-best-human-surgeons-have-just-five-years-before-robots-overtake-them-reveals-instance-when-neuralink-had-to-use-a-robot-for-task-impossible-for-a-human">Elon Musk Says Best Human Surgeons Will Be Outdone By Robots In Almost 5 Years, Cites Example Of His Own Brain-Chip Company</a>

ETFs

ARKK

ARKX

PLTR

Cathie Wood Sees Palantir Dominating Enterprise AI, Wonders How Microsoft Will Manage 'Massive Disruption' — Will Excel Finally Die?

<ul>
<li>Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profile</li>
<li>Abpro and Celltrion have a strategic partnership for worldwide development and commercialization of ABP-102/CT-P72</li>
<li>HER2-positive cancers represent up to 30 percent of all cases of breast, gastric, pancreatic, colorectal and other forms of cancer</li>
</ul>

Reported Sunday, Abpro And Celltrion Present Preclinical Data For ABP-102/CT-P72, Showcasing Potential Best-In-Class HER2 X CD3 T-Cell Engager

President Donald Trump vowed Sunday to "bring Columbus Day back from the ashes." 
What Happened: Trump pledged on Truth Social to restore the federal holiday "under the same rules, dates, and locations" it held for decades. 
"The Democrats did everything possible to destroy Christopher Columbus, his reputation, and all of the Italians that love him so much," he wrote, adding that statues toppled during racial-justice protests would see a "major comeback."
Trump's declaration reignites a long-running culture clash over the second Monday in October. In 2021, former President Joe Biden became the first sitting president to <a href="https://bidenwhitehouse.archives.gov/briefing-room/presidential-actions/2021/10/08/a-proclamation-indigenous-peoples-day-2021/">issue a proclamation</a> recognizing Indigenous Peoples Day, noting the "resilience and strength" of Native communities and the "systematic" federal policies that once sought to erase them. Many cities and states have since replaced or paired Columbus Day with observances honoring Indigenous history.
See also: <a href="https://www.benzinga.com/markets/25/04/45030778/trump-running-american-economy-like-a-mafia-don-economist-craig-shapiro-draws-parallels-with-russias-president">Trump Running American Economy Like A &#8216;Mafia Don&#8217;: Economist Craig Shapiro Draws Parallels With Russia&#8217;s President</a>
During his first term, Trump routinely praised Columbus as a symbol of exploration, saying in a <a href="https://trumpwhitehouse.archives.gov/presidential-actions/presidential-proclamation-columbus-day-2018/">2018 proclamation</a> that the navigator's voyage "formed the initial bond between Europe and the Americas, and changed the world forever." He never referenced Indigenous Peoples Day.
Why It Matters: Trump's promise to elevate Columbus Day fits in with his broader campaign against what he calls "woke" initiatives, from scrapping federal <a href="https://www.benzinga.com/25/03/44344917/trumps-ban-on-dei-programs-allowed-for-now-by-appeals-court">diversity-equity programs</a> to <a href="https://www.benzinga.com/25/04/44804541/trump-administration-halts-2-2-billion-in-harvard-grants-after-university-says-dont-dictate-what-we-can-teach-or-who-we-admit">threatening to pull funds</a> from universities that adopt policies he opposes. The former president has repeatedly criticized teaching U.S. history through themes of oppression and race, casting his holiday push as another salvo in that culture war.
Ironically, Columbus Day itself was conceived as a tribute to diversity, <a href="https://apnews.com/article/trump-columbus-indigenous-peoples-day-biden-ee34f1873a9af8ea85ac732b9edf82fc">according</a> to the Associated Press. Lawmakers embraced the explorer in the late 19th century to court Italian-American voters as immigration from Italy surged. Columbus never reached the future United States, but his Genoese roots offered a convenient symbol for newcomers seeking acceptance — and for politicians eager to win their support.
Photo Courtesy: Rawpixel.com on Shutterstock.com
Read next: <a href="https://www.benzinga.com/25/04/45031652/trumps-ai-and-crypto-czar-david-sacks-says-musk-isnt-out-of-doge-just-rationing-his-time-at-the-department-as-tesla-stock-surges-24-in-the-past-five-days">Trump&#8217;s AI And Crypto Czar David Sacks Says Elon Musk Going To &#8216;Stay Involved&#8217; In DOGE, Calls Entrepreneur Rationing His Time Sensible</a>

Government

Regulations

Events

Trump Vows To Bring Back Columbus Day 'From The Ashes,' Promises To Restore 'Same Rules, Dates And Locations'

<ul>
<li>Long-term data from the Volt&nbsp;CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt&#x2122; PFA System</li>
<li>The 12-month results of the Volt&nbsp;CE Mark Study confirm the long-term safety and efficacy of the Volt PFA System</li>
<li>The data were presented at the 2025 Heart Rhythm Society (HRS) annual meeting</li>
</ul>

Reported Saturday, Abbott Presents New Volt PFA System Data Highlighting Outstanding Long-Term Safety And Freedom From Arrhythmia At 12 Months

<ul>
<li>Late-breaking data from Abbott's groundbreaking first-in-human study demonstrated successful implantation of the company's AVEIR Conduction System Pacing (CSP) leadless pacemaker</li>
<li>Enrollment has also begun in the ASCEND CSP pivotal clinical trial to evaluate Abbott's investigational CSP Implantable Cardioverter-Defibrillator (ICD) lead</li>
<li>Conduction System Pacing is an evolving technique specifically designed to deliver pacing to the left bundle branch area of the heart to restore its natural electrical rhythm</li>
</ul>

Reported Sunday, Abbott's AVEIR CSP Study Demonstrates First Successful Leadless Conduction System Pacing In Left Bundle Branch Area

YMAB

Reported Sunday, Y-mAbs Highlights Preclinical And Translational PK Modeling Of CD38-SADA Bispecific Fusion Protein At AACR 2025

URGN

Reported Sunday, UroGen Highlights Nearly Four-Year Duration Of Response In OLYMPUS Long-Term Follow-Up Study Of JELMYTO

<ul>
<li>New analysis of patient-reported outcomes from the OPTIMA II, ATLAS and ENVISION studies of UGN-102 presented at the American Urological Association (AUA) 2025 Annual Meeting in Las Vegas, Nevada</li>
</ul>

Reported Sunday, UroGen Presents New Data Showing UGN-102 Does Not Adversely Affect Functionality or Symptom Burden

Reported Sunday, UroGen's OPTIMA II Study Results Show UGN-102 Delivers Median 24.2-Month Duration Of Response In Recurrent LG-IR-NMIBC

<ul>
<li>18-month DOR of 80.6% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%)</li>
<li>Data unveiled during a Podium Presentation at the American Urological Association (AUA) 2025 Annual Meeting in Las Vegas, Nevada</li>
</ul>

Reported Saturday, UroGen Pharma's UGN-102 Achieves 80.6% Probability Of Sustained Complete Response At 18 Months In Phase 3 ENVISION Trial

<ul>
<li>UGN-301 was tolerated across all dose levels, with no dose-limiting toxicities or adverse events leading to treatment discontinuation</li>
<li>UGN-301 formulated in a reverse thermal gel allowed sustained exposure in the bladder</li>
<li>Some patients receiving UGN-301 (zalifrelimab) intravesical solution showed clinical activity at the week 12 disease assessment</li>
<li>Data presented at the 2025 American Urological Association Annual Meeting in Las Vegas, Nevada</li>
</ul>

Reported Saturday, UroGen Pharma's UGN-301 Phase 1 Trial Shows Sustained Bladder Exposure And No Dose-Limiting Toxicities In Non-Muscle Invasive Bladder Cancer

Nuveen California Dividend Advantage Municipal Fund 2

Reported Earlier, NOVONIX Names Michael O'Kronley CEO, Effective May 19

IOTR

Reported Earlier, iO3's F.R.I.D.A.Y Planned Maintenance System Secures ClassNK Approval, Paving Way For Maritime Digitalization

Management

Press Releases

Fusion Fuel Appoints Luisa Ingargiola to Board of Directors

Avalon GloboCare and YOOV, a Leading Business AI Automation Solutions Provider, Enter into Merger Agreement

Shareholder Alert: The Ademi Firm investigates whether Avalon GloboCare Corp. is obtaining a Fair Price for its Public Shareholders

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Avalon GloboCare Corp. - ALBT

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Avalon GloboCare Corp. - ALBT

ALBT Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Avalon GloboCare Corp. is Fair to Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JWN and ALBT on Behalf of Shareholders

Health Care

Avalon GloboCare Partners with Pounds Transformation Clinics to Unveil the KetoAir BrAce 4 Impact Challenge Series

Avalon GloboCare Announces Issuance of Patent for Novel CAR-T and CAR-NK Cell Technology in China

Avalon GloboCare Partners with SpecialtyHealth, Inc. to Power Police Chiefs' Fitness Challenge with KetoAir

ALBT

BICX

HTOO

VMAR

American Realty Investors, Inc. Common Stock

American Realty Investors

FRP Holdings

New Concept Energy

The Intergroup Corporation - Common Stock

Intergroup

IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of Common Stock)

IRSA Inversiones y

Kennedy-Wilson Holdings Inc. Common Stock

Kennedy-Wilson Holdings

LandBridge Company LLC Class A Shares Representing Limited Liability Company Interests

LandBridge

Logistic Properties of the Americas Ordinary Shares

Logistic Properties

J. W. Mays

Maui Land & Pineapple Company, Inc. Common Stock

Maui Land & Pineapple Co

Murano Global Investments PLC - Ordinary Shares

Murano Global Investments

New England Realty Associates Limited Partnership Class A Depositary Receipts Evidencing Units of Limited Partnership

New England Realty

American Strategic Investment Co. Class A Common Stock

American Strategic

Belpointe PREP

Rafael Holdings, Inc. Class B Common Stock

Rafael Holdings

Reitar Logtech Holdings Limited - Ordinary shares

Reitar Logtech Holdings

Seaport Entertainment Group Inc. Common Stock

Seaport Entertainment

Seritage Growth Properties Class A Common Stock

Seritage Growth Props

Transcontinental Realty Investors, Inc. Common Stock

Transcontinental Realty

Corporacion Inmobiliaria Vesta, S.A.B de C.V. American Depositary Shares, each representing ten (10) Common Shares

Comments

Avalon Globocare

ニュース

最新ニュース Avalon Globocare (NASDAQ:ALBT) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル